It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.
It may be possible to collect nearly three times as many stem cells for gene therapy for sickle cell disease (SCD) with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback